Potency of clinical group B streptococcal conjugate vaccines.

[1]  D. Kasper,et al.  Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. , 2000, The Journal of infectious diseases.

[2]  D. Kasper,et al.  Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. , 2000, The Journal of infectious diseases.

[3]  A. Schuchat,et al.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.

[4]  D. Kasper,et al.  Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. , 1999, The Journal of infectious diseases.

[5]  D. Kasper,et al.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.

[6]  D. Kasper,et al.  Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. , 1997, The Journal of infectious diseases.

[7]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[8]  D. Kasper,et al.  Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons , 1996, Infection and immunity.

[9]  D. Kasper,et al.  Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1995, The Journal of infectious diseases.

[10]  D. Kasper,et al.  Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. , 1994, The Journal of clinical investigation.

[11]  D. Kasper,et al.  Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine , 1993, Infection and immunity.

[12]  D. Kasper,et al.  Neonatal mouse model of group B streptococcal infection. , 1992, The Journal of infectious diseases.

[13]  D. Kasper,et al.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of clinical investigation.

[14]  J. Shiloach,et al.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid , 1990, Infection and immunity.

[15]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .